Hims & Hers Health (NYSE:HIMS) Releases Quarterly Earnings Results, Misses Expectations By $0.32 EPS

Hims & Hers Health (NYSE:HIMS) announced its quarterly earnings results on Monday. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.32), FiscalAI reports. Hims & Hers Health had a negative net margin of 0.56% and a positive return on equity of 6.10%. The firm had revenue of $753.21 million during the quarter, compared to analysts’ expectations of $698.90 million.

Here are the key takeaways from Hims & Hers Health’s conference call:

• Revenue and subscriber growth accelerated. Q2 revenue rose nearly 40% year over year to more than $753 million, with 300,000 net new subscribers bringing the total to nearly 3 million; management raised full-year 2026 revenue guidance to $3.1 billion–$3.3 billion.
• The company reported early benefits from its AI-native care platform, including three times more customer messaging, an approximately 50% reduction in non-clinical support tasks, and lower cancellation rates in pilot cohorts. Management expects AI investments to pay back within 12–18 months and support improved retention and cost efficiency.
• International expansion is becoming a major growth driver following the Eucalyptus acquisition. International revenue increased more than 17-fold year over year to $131 million, and the company expects international revenue of at least $600 million in 2026 while expanding U.S. specialties such as testosterone, sexual health, and dermatology overseas.
• New growth opportunities include injectable and oral testosterone before year-end and peptide-related wellness offerings, subject to regulatory developments. The company expects to launch already permitted offerings such as sermorelin, glutathione, and NAD+ by year-end, while awaiting final FDA rulemaking for additional peptides.
• Profitability and cash flow faced near-term pressure from the business mix and one-time costs. Adjusted gross margin fell to 64% as branded weight-loss products and international revenue grew, Q2 free cash flow was negative $68 million, and the company incurred approximately $81 million in acquisition, restructuring, and FTC-related legal costs; management also said international operations may remain near breakeven as it invests for scale.

Hims & Hers Health Stock Up 0.7%

HIMS stock traded up $0.22 during trading on Monday, hitting $31.81. 17,006,446 shares of the company’s stock traded hands, compared to its average volume of 26,837,846. The firm has a market capitalization of $7.36 billion, a P/E ratio of -353.44, a PEG ratio of 88.90 and a beta of 2.40. Hims & Hers Health has a 1 year low of $13.74 and a 1 year high of $65.30. The company has a quick ratio of 1.56, a current ratio of 1.69 and a debt-to-equity ratio of 2.18. The business has a fifty day simple moving average of $31.86 and a two-hundred day simple moving average of $26.06.

Insider Activity at Hims & Hers Health

In related news, insider Irene Becklund sold 4,490 shares of the company’s stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $31.50, for a total transaction of $141,435.00. Following the completion of the sale, the insider directly owned 6,790 shares in the company, valued at $213,885. This represents a 39.80% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, COO Michael Chi sold 14,027 shares of the company’s stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $31.50, for a total value of $441,850.50. Following the sale, the chief operating officer owned 432,124 shares of the company’s stock, valued at $13,611,906. This trade represents a 3.14% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 83,126 shares of company stock valued at $2,711,339 over the last 90 days. Insiders own 11.76% of the company’s stock.

Hedge Funds Weigh In On Hims & Hers Health

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. State Street Corp raised its holdings in Hims & Hers Health by 1.8% in the fourth quarter. State Street Corp now owns 7,305,525 shares of the company’s stock worth $237,210,000 after purchasing an additional 132,311 shares in the last quarter. Invesco Ltd. lifted its position in shares of Hims & Hers Health by 62.7% during the third quarter. Invesco Ltd. now owns 4,152,409 shares of the company’s stock valued at $235,525,000 after buying an additional 1,600,004 shares during the last quarter. Marex Group plc boosted its holdings in shares of Hims & Hers Health by 162.2% in the 4th quarter. Marex Group plc now owns 2,419,518 shares of the company’s stock valued at $78,562,000 after buying an additional 1,496,707 shares in the last quarter. Northern Trust Corp boosted its holdings in shares of Hims & Hers Health by 1.4% in the 3rd quarter. Northern Trust Corp now owns 2,415,158 shares of the company’s stock valued at $136,988,000 after buying an additional 32,236 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in shares of Hims & Hers Health by 1.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 2,398,008 shares of the company’s stock worth $77,863,000 after buying an additional 42,569 shares during the last quarter. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Key Stories Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Second-quarter revenue rose to $753.2 million, surpassing the $698.9 million analyst consensus. The company attributed the performance to strong subscriber growth and broader personalized healthcare offerings. Reuters article
• Positive Sentiment: Hims & Hers raised its 2026 revenue forecast to $3.1 billion-$3.3 billion from $2.8 billion-$3.0 billion, above the approximately $3.0 billion consensus estimate. Wall Street Journal article
• Positive Sentiment: Third-quarter revenue guidance of $880 million-$900 million also exceeded the $845.9 million analyst estimate, reinforcing expectations for continued demand and subscriber expansion.
• Neutral Sentiment: The company said nearly 3 million people rely on its platform, while commentary surrounding the GLP-1 market remains a potential long-term growth catalyst. Company earnings release
• Negative Sentiment: Hims & Hers reported a quarterly loss of $0.37 per share, missing the $0.05 loss expected by analysts by $0.32. The earnings shortfall appears to be the primary reason the stock has moved lower despite the revenue beat and improved outlook. Benzinga article
• Negative Sentiment: Several law firms announced investigations into potential securities-law violations or breaches of fiduciary duty related to Hims & Hers. These announcements may add headline risk and increase investor concerns, although no wrongdoing has been established. Scott+Scott investigation

Analyst Ratings Changes

Several research analysts have commented on HIMS shares. Jefferies Financial Group set a $24.50 price objective on Hims & Hers Health in a report on Tuesday, May 12th. Weiss Ratings downgraded Hims & Hers Health from a “hold (c)” rating to a “sell (d)” rating in a research report on Tuesday, May 12th. JPMorgan Chase & Co. cut their price target on Hims & Hers Health from $35.00 to $33.00 and set an “overweight” rating on the stock in a research note on Tuesday, May 12th. Wall Street Zen downgraded Hims & Hers Health from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Finally, Barclays upped their price objective on shares of Hims & Hers Health from $29.00 to $39.00 and gave the stock an “overweight” rating in a research note on Wednesday, June 17th. Four research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $31.43.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.